Clinical Trials
108 trialsAndroMETa-CRC
AbbVie
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
MK-3475-C66
Merck Sharp & Dohme LLC
A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.
Pfizer
A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors
Crossignal Therapeutics, Inc.
BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours
Bold Therapeutics, Inc.
A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer
Ono Pharmaceutical Co., Ltd.
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Parabilis Medicines, Inc.
OrigAMI-1
Janssen Research & Development, LLC
OrigAMI-2
Janssen Research & Development, LLC
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
Pfizer
HARMONi-GI3
Summit Therapeutics
A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
Tyligand Pharmaceuticals (Suzhou) Limited
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
Seagen Inc.
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
Pfizer
MOONRAY-01
Eli Lilly and Company
A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
An Exploratory Study of Treatment Sensitivity and Prognostic Factors in a Efficacy and Safety Study of mFOLFOX6 + Bevacizumab Versus mFOLFOX6 + Panitumumab Therapy in Patients With Chemotherapy-naïve Unresectable Advanced or Recurrent Colorectal Cancer
Takeda
MOUNTAINEER-03
Seagen Inc.
Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers
Novartis
A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer
Multitude Therapeutics Inc.
A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal Cancer
Akeso
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
Seagen Inc.
A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer
Enliven Therapeutics
A Phase II/III Study of HR070803 in Combination With Oxaliplatin, 5-fluorouracil, Calcium Folinate and Bevacizumab Versus FOLFOX in Combination With Bevacizumab for First-line Treatment of Advanced Colorectal Cancer
Jiangsu HengRui Medicine Co., Ltd.
A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers
Shenyang Sunshine Pharmaceutical Co., LTD.
A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer
Akeso
CheckMate 8HW
Bristol-Myers Squibb
A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
Jazz Pharmaceuticals
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
Pfizer
A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors
Incyte Corporation
QL1706 Injection Plus Bevacizumab and XELOX vs Placebo Plus Bevacizumab and XELOX as First-Line Treatment of Unresectable Metastatic Colorectal Cancer
Qilu Pharmaceutical Co., Ltd.
Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors
DEKA Biosciences
A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors
Jiangsu Hansoh Pharmaceutical Co., Ltd.
QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC
ImmunityBio, Inc.
ARTEMIS-102: HS-20093 Combinations in Patients with Advanced Metastatic Colorectal Cancer
Hansoh BioMedical R&D Company
QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine
ImmunityBio, Inc.
KEYNOTE-651
Merck Sharp & Dohme LLC
IVY
Eli Lilly and Company
A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Study of ONO-4578 and XELOX/FOLFOX Plus Bevacizumab in Colorectal Cancer
Ono Pharmaceutical Co., Ltd.
Study of S 95005 in Combination With Oxaliplatin in Metastatic Colorectal Cancer
Servier
CheckMate 9X8
Bristol-Myers Squibb
PARADIGM
Takeda
A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors
Cantargia AB
QL1706 Monotherapy or in Combination With Bevacizumab and XELOX as First-line Treatment of Unresectable Advanced or Metastatic CRC
Qilu Pharmaceutical Co., Ltd.
A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
Incyte Corporation
MB-6
Microbio Co Ltd
Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRC
MedImmune LLC